Global phase 2 data in TNBC look similar to earlier results in China.
ApexOnco Front Page
Recent articles
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
The company might have blown Enliven out of the water.
Studies presented at ASH show this to be true only up to a point.
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.
Pfizer reveals the discontinuation of PF-08046044.
On efficacy, at least, BeOne’s BTK degrader shows an edge.
